Gemcitabine has been noted as the first line of defense for pancreatic cancer, but its efficacy is being decreased by the chemoresistance caused by NF-κB, which prevents improvements in survival rates and prognosis. Here, NFKB1 is linked to familial pancreatic carcinoma.